Patient preferences for epilepsy treatment: a systematic review of discrete choice experimental studies

[1]  S. Sinha,et al.  Patient preferences pertaining to treatment options for drug-resistant focal epilepsy , 2022, Epilepsy & Behavior.

[2]  F. Villani,et al.  Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: Discrete choice experiment eliciting preferences in real‐world study "VOTE" , 2021, Epilepsia.

[3]  D. Pitocco,et al.  The role of patient preferences in adherence to treatment in chronic disease: a narrative review , 2021, Drug target insights.

[4]  J. Illes,et al.  Understanding Attributes that Influence Physician and Caregiver Decisions About Neurotechnology for Pediatric Drug-Resistant Epilepsy: A Formative Qualitative Study to Support the Development of a Discrete Choice Experiment , 2021, The Patient - Patient-Centered Outcomes Research.

[5]  T. Tervonen,et al.  A Systematic and Critical Review of Discrete Choice Experiments in Asthma and Chronic Obstructive Pulmonary Disease , 2021, The Patient - Patient-Centered Outcomes Research.

[6]  J. Veldwijk,et al.  Methodological Priorities for Patient Preferences Research: Stakeholder Input to the PREFER Public–Private Project , 2021, The Patient - Patient-Centered Outcomes Research.

[7]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: An updated guideline for reporting systematic reviews , 2021, PLoS medicine.

[8]  Yingjie Hua,et al.  Patient Preference for Antiepileptic Drugs Treatment in China: Evidence From the Discrete Choice Experiment , 2020, Frontiers in Neurology.

[9]  W. Berta,et al.  How to identify, incorporate and report patient preferences in clinical guidelines: A scoping review , 2020, Health expectations : an international journal of public participation in health care and health policy.

[10]  K. Vermeulen,et al.  Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands , 2020, PloS one.

[11]  K. Marsh,et al.  Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  M. Hiligsmann,et al.  The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments , 2020, Current medical research and opinion.

[13]  S. Straus,et al.  How do guideline developers identify, incorporate and report patient preferences? An international cross-sectional survey , 2020, BMC Health Services Research.

[14]  M. Hiligsmann,et al.  Patients’ preferences for the treatment of anxiety and depressive disorders: a systematic review of discrete choice experiments , 2020, Journal of medical economics.

[15]  Steven Simoens,et al.  Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review , 2019, BMC Medical Informatics and Decision Making.

[16]  A. Bergland,et al.  The James Lind Alliance process approach: scoping review , 2019, BMJ Open.

[17]  I. Huys,et al.  Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. , 2019, Drug discovery today.

[18]  A. Marson,et al.  Patient‐Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs , 2018, Clinical pharmacology and therapeutics.

[19]  Alan R. Ellis,et al.  Discrete Choice Experiments in Health Economics: Past, Present and Future , 2018, PharmacoEconomics.

[20]  K. Rajagopalan,et al.  Patient versus neurologist preferences: A discrete choice experiment for antiepileptic drug therapies , 2018, Epilepsy & Behavior.

[21]  M. Hiligsmann,et al.  A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs , 2018, Epilepsy & Behavior.

[22]  Anna Selva,et al.  Development and use of a content search strategy for retrieving studies on patients' views and preferences , 2017, Health and Quality of Life Outcomes.

[23]  Katherine Payne,et al.  Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet? , 2017, PharmacoEconomics.

[24]  M. Hiligsmann,et al.  Patients’ Preferences for Outcome, Process and Cost Attributes in Cancer Treatment: A Systematic Review of Discrete Choice Experiments , 2017, The Patient - Patient-Centered Outcomes Research.

[25]  Caroline Vass,et al.  The Role of Qualitative Research Methods in Discrete Choice Experiments , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  A. Booth,et al.  The development of PubMed search strategies for patient preferences for treatment outcomes , 2016, BMC Medical Research Methodology.

[27]  Timea Mariann Helter,et al.  Developing attributes for discrete choice experiments in health: a systematic literature review and case study of alcohol misuse interventions , 2016, Journal of substance use.

[28]  Tanjala S. Purnell,et al.  Patient Preferences for the Treatment of Type 2 Diabetes: A Scoping Review , 2013, PharmacoEconomics.

[29]  A. Lloyd,et al.  Patient preferences for therapies in Epilepsy , 2013 .

[30]  A. Mühlbacher,et al.  Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making? , 2013, Applied Health Economics and Health Policy.

[31]  Deborah Marshall,et al.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  R. Manjunath,et al.  Patients' preferences for treatment outcomes of add-on antiepileptic drugs: A conjoint analysis , 2012, Epilepsy & Behavior.

[33]  Mickael Bech,et al.  Designing a stated choice experiment: The value of a qualitative process , 2012 .

[34]  E. McIntosh,et al.  The importance of drug adverse effects compared with seizure control for people with epilepsy , 2012, PharmacoEconomics.

[35]  Jonathan N. Hawley,et al.  Caregiver measures for seizure control, efficacy, and tolerability of antiepileptic drugs for childhood epilepsy: Results of a preference survey , 2011, Epilepsy & Behavior.

[36]  Andrew Lloyd,et al.  Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[37]  J. Louviere,et al.  Discrete Choice Experiments Are Not Conjoint Analysis , 2010 .

[38]  Emily Lancsar,et al.  Choice experiments in health: the good, the bad, the ugly and toward a brighter future , 2009, Health Economics, Policy and Law.

[39]  Murray Krahn,et al.  The next step in guideline development: incorporating patient preferences. , 2008, JAMA.

[40]  Josemir W Sander.  Ultimate success in epilepsy – the patient's perspective , 2005, European journal of neurology.

[41]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[42]  M Ryan,et al.  Eliciting public preferences for healthcare: a systematic review of techniques. , 2001, Health technology assessment.

[43]  M Lindsay,et al.  Epilepsy in adults. , 1983, Nursing.